Compendium of Cancer Genome Aberrations

CNS5:Volunteer Assignments and Opportunities: Difference between revisions

← Older edit
VisualWikitext
No edit summary
m due date
 
(36 intermediate revisions by 5 users not shown)
Line 6: Line 6:


To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br />
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br />
__TOC__
{| class="wikitable" style="margin:auto"
{| class="wikitable" style="margin:auto"
|+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big>
|+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big>
Line 17: Line 18:
!'''Notes'''
!'''Notes'''
|-
|-
|CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS)
|
====CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS)====
|
|
----
----
Line 42: Line 44:
|6/25/2023
|6/25/2023
|
|
|PENDING
|COMPLETE
|
|
|Laveniya Satgunaseelan (LS)
|Laveniya Satgunaseelan (LS)
Line 50: Line 52:
|[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]]
|[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]]
|Disease
|Disease
|Riley Lochner (trainee), Shashi Shetty (mentor)
|Riley Lochner (trainee);
Shashi Shetty (mentor)
|6/7/2022
|6/7/2022
|
|
Line 61: Line 64:
|[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]]
|[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]]
|Disease
|Disease
|Meenakshi Mehrotra
|Jieying Wu
|
|11/18/2025
|
|01/15/2026
|PENDING
|PENDING
|
|
Line 75: Line 78:
|6/27/2023
|6/27/2023
|
|
|PENDING
|COMPLETE
|
|
|LS
|LS
Line 108: Line 111:
|5/3/2024
|5/3/2024
|
|
|PENDING
|PENDING - email reminder 9/4/2025
|
|
|LS
|LS
Line 116: Line 119:
|[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]]
|[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]]
|Disease
|Disease
|Laveniya Satgunaseelan (Linda Cooley - previous version)
|Laveniya Satgunaseelan
|
|
|
|
|PENDING
|COMPLETE
|
|
|LS
|LS
Line 135: Line 138:
|
|
|2021 template added
|2021 template added
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]]
|[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]]
Line 160: Line 174:
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]]
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]]
|Disease
|Disease
|Jeremy Pulvers
|Layla Zhu
|9/13/2022<br />
|<br />3/2/2026
|
|
|PENDING
|PENDING
Line 171: Line 185:
|[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]]
|[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]]
|Disease
|Disease
|Wahab Khan
|2/8/2026
|
|
|
|PENDING
|
|
|
|
|
|
Line 182: Line 196:
|[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]]
|[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]]
|Disease
|Disease
|Wahab Khan
|15/04/2025
|
|
|
|COMPLETE
|
|2/8/2026 (Feb 8)
|
|
|LS
|LS
|
|
Line 215: Line 229:
|[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]]
|[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]]
|Disease
|Disease
|Milana.Djonovic (trainee), Laveniya/Madina
|4/26/2026
|6/15/2026
|PENDING
|
|
|
|LS
|
|
|
|
|
|
|
|
Line 245: Line 259:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]]
|[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]]
Line 314: Line 339:
|[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]]
|[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]]
|Disease
|Disease
|Laveniya Satgunaseelan
|9/11/2024
|
|
|
|COMPLETE
|
|8/7/2025
|
|LS
|
|LS
|
|Used for testing 9/2024 somatic template
|
|
|-
|-
|[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]]
|[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]]
Line 356: Line 381:
|
|
|-
|-
|[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]]
!'''Disease'''
|Disease
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]]
|Disease
|
|
|
|
Line 380: Line 416:
|[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]]
|[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]]
|Disease
|Disease
|
|Laveniya Satgunaseelan
|
|2/4/2026
|
|30/6/2026
|
|PENDING
|
|
|
|
Line 391: Line 427:
|[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]]
|[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]]
|Disease
|Disease
|
|Laveniya Satgunaseelan
|
|2/4/2026
|
|30/6/2026
|
|PENDING
|
|
|
|
Line 402: Line 438:
|[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]]
|[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]]
|Disease
|Disease
|
|Laveniya Satgunaseelan
|
|2/4/2026
|
|30/6/2026
|
|PENDING
|
|
|
|
Line 465: Line 501:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]]
|[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]]
Line 488: Line 535:
|
|
|-
|-
|CHAPTER 3 (CHOROID PLEXUS TUMOURS)
|
====CHAPTER 3 (CHOROID PLEXUS TUMOURS)====
|
|
----
----
Line 541: Line 589:
|
|
|-
|-
|CHAPTER 4 (EMBRYONAL TUMOURS)
|
====CHAPTER 4 (EMBRYONAL TUMOURS)====
|
|
----
----
Line 563: Line 612:
|[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]]
|[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]]
|Disease
|Disease
|Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|Lisa Lansdon, PhD (LGG trainee just finished);
Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|9/20/21
|9/20/21
|
|
Line 585: Line 635:
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]]
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]]
|Disease
|Disease
|Hannah Wollenzien
|1/11/2026
|
|
|Pending
|
|
|MS
|
|
|
|
|
|-
|
!'''Disease'''
|
!'''Page Type'''
|
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]]
|[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]]
Line 682: Line 743:
|
|
|-
|-
|CHAPTER 5 (PINEAL TUMOURS)
|
====CHAPTER 5 (PINEAL TUMOURS)====
|
|
----
----
Line 712: Line 774:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]]
|[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]]
Line 726: Line 799:
|[[CNS5:Pineoblastoma|Pineoblastoma]]
|[[CNS5:Pineoblastoma|Pineoblastoma]]
|Disease
|Disease
|Fang Fang (trainee)+Katie Schieffer (mentor)
|11/19/2025
|6/15/2026
|Pending
|
|
|
|LS
|
|
|
|
|
|
|
|
Line 757: Line 830:
|
|
|-
|-
|CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS)
|
====CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS)====
|
|
----
----
Line 779: Line 853:
|[[CNS5:Schwannoma|Schwannoma]]
|[[CNS5:Schwannoma|Schwannoma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Neurofibroma|Neurofibroma]]
|[[CNS5:Neurofibroma|Neurofibroma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Perineurioma|Perineurioma]]
|[[CNS5:Perineurioma|Perineurioma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]]
|[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]]
|[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]]
|Disease
|Disease
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
!'''Disease'''
|
!'''Page Type'''
|
!'''<span style="color:#0070C0">Author'''
|
!'''Date Assigned to Author'''
|
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]]
|Disease
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|-
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]]
|[[CNS5:Cauda_equina_neuroendocrine_tumour_(previously_paraganglioma)|Cauda equina neuroendocrine tumour (previously paraganglioma)]]
|Disease
|Disease
|
|
Line 843: Line 939:
|
|
|-
|-
|[[CNS5:Cauda_equina_neuroendocrine_tumour_(previously_paraganglioma)|Cauda equina neuroendocrine tumour (previously paraganglioma)]]
|
|Disease
====CHAPTER 7 (MENINGIOMA)====
|
|
|
|
|
|
|
|
|-
|CHAPTER 7 (MENINGIOMA)
|
|
----
----
Line 885: Line 971:
|
|
|-
|-
|CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS)
|
====CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS)====
|
|
----
----
Line 907: Line 994:
|[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 960: Line 1,047:
|
|
|-
|-
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 984: Line 1,082:
|[[CNS5:Ewing_sarcoma|Ewing sarcoma]]
|[[CNS5:Ewing_sarcoma|Ewing sarcoma]]
|Disease
|Disease
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|
|
|
|
|
|-
|[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]]
|[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,026: Line 1,124:
|
|
|-
|-
|CHAPTER 9 (MELANOCYTIC TUMOURS)
|
====CHAPTER 9 (MELANOCYTIC TUMOURS)====
|
|
----
----
Line 1,068: Line 1,167:
|
|
|-
|-
|CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS)
|
====CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS)====
|
|
----
----
Line 1,099: Line 1,199:
|
|
|-
|-
|[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]]
!'''Disease'''
|Disease
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]]
|Disease
|
|
|
|
Line 1,112: Line 1,223:
|[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]]
|[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]]
|[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]]
|Disease
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]]
|
|
|
|
|
|-
|[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,178: Line 1,289:
|[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]]
|[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]]
|[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]]
|[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]]
|Disease
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
!'''Disease'''
|
!'''Page Type'''
|
!'''<span style="color:#0070C0">Author'''
|
!'''Date Assigned to Author'''
|
!'''Target Completion Date'''
|
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]]
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]]
|[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]]
|Disease
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|
|
|
====CHAPTER 11 (GERM CELL TUMOURS)====
|
|
|
|
|
|-
|CHAPTER 11 (GERM CELL TUMOURS)
|
|
----
----
Line 1,262: Line 1,385:
|
|
|-
|-
|CHAPTER 12 (TUMOURS OF THE SELLAR REGION
|
====CHAPTER 12 (TUMOURS OF THE SELLAR REGION====
|
|
----
----
Line 1,337: Line 1,461:
|
|
|-
|-
|CHAPTER 13 (METASTASES TO THE CNS)
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|
====CHAPTER 13 (METASTASES TO THE CNS)====
|
|
----
----
Line 1,379: Line 1,515:
|
|
|-
|-
|CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS)
|
====CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS)====
|
|
----
----
Line 1,401: Line 1,538:
|[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
|[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
|Disease
|Disease
|Ngoni Faya (trainee) + Madina Sukhanova
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|N/A
|N/A
|N/A
|
|
|
|
|NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
|-
|-
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]]
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Schwannomatosis|Schwannomatosis]]
|[[CNS5:Schwannomatosis|Schwannomatosis]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,441: Line 1,578:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]]
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]]
|[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]]
|Disease
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
!'''Disease'''
|
!'''Page Type'''
|
!'''<span style="color:#0070C0">Author'''
|
!'''Date Assigned to Author'''
|
!'''Target Completion Date'''
|
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Cowden_syndrome|Cowden syndrome]]
|[[CNS5:Cowden_syndrome|Cowden syndrome]]
|Disease
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]]
|
|
|
|
|
|-
|[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]]
|Disease
|Disease
|Jennie Thurston
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|7/2/2023
|N/A
|
|N/A
|PENDING
|N/A
|N/A
|N/A
|N/A
|
|
|LS
|
|NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
|-
|-
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]]
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]]
Line 1,496: Line 1,644:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]]
|[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]]
|[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Carney_complex|Carney complex]]
|[[CNS5:Carney_complex|Carney complex]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:DICER1_syndrome|DICER1 syndrome]]
|[[CNS5:DICER1_syndrome|DICER1 syndrome]]
|Disease
|Disease
|Jennie Thurston
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|7/2/2023
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|PENDING
|
|LS
|
|NOT YET CREATED - See page "''DICER1''-Related Tumour Predisposition Syndrome (''DICER1'')" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
|-
|-
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]]
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]]
|[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,575: Line 1,723:
|
|
|-
|-
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]]
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Fanconi_anaemia|Fanconi anaemia]]
|[[CNS5:Fanconi_anaemia|Fanconi anaemia]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]]
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|}
|}
Retrieved from "https://content.ccga.io/index.php/CNS5:Volunteer_Assignments_and_Opportunities"